These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11742895)

  • 1. Pharmacoeconomics in pediatric asthma.
    McIvor RA
    Chest; 2001 Dec; 120(6):1762-3. PubMed ID: 11742895
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children.
    Bisgaard H; Price MJ; Maden C; Olsen NA
    Chest; 2001 Dec; 120(6):1835-42. PubMed ID: 11742910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
    O'Connor RD; Nelson H; Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
    Pharmacoeconomics; 2004; 22(12):815-25. PubMed ID: 15294013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
    Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
    Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative resource utilization in medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy.
    Stanford RH; Riedel AA; Johnson JC; Astry CL
    Clin Ther; 2010 Sep; 32(10):1782-93. PubMed ID: 21194602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate.
    Pharmacoeconomics; 1999; 16 Suppl 2():i-viii, 1-34. PubMed ID: 10724799
    [No Abstract]   [Full Text] [Related]  

  • 7. Invalid and irrelevant comparisons: apples or oranges?
    Currie GP; Carter K
    Ann Allergy Asthma Immunol; 2006 Feb; 96(2):379. PubMed ID: 16498865
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.
    Lamb HM; Culy CR; Faulds D
    Pharmacoeconomics; 2000 Nov; 18(5):487-510. PubMed ID: 11151402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective.
    Paggiaro P; Patel S; Nicolini G; Pradelli L; Zaniolo O; Papi A
    Respir Med; 2013 Oct; 107(10):1531-7. PubMed ID: 23916740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
    Markham A; Jarvis B
    Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mometasone furoate vs fluticasone propionate with salmeterol: multivariate analysis of resource use and asthma-related charges.
    Navaratnam P; Friedman HS; Urdaneta E
    Curr Med Res Opin; 2009 Dec; 25(12):2895-901. PubMed ID: 19821655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.
    Menendez R; Stanford RH; Edwards L; Kalberg C; Rickard K
    Pharmacoeconomics; 2001; 19(8):865-74. PubMed ID: 11596838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebulised fluticasone.
    Todd GR
    Thorax; 2000 Apr; 55(4):346-7. PubMed ID: 10766646
    [No Abstract]   [Full Text] [Related]  

  • 14. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma.
    Miller E; Sears MR; McIvor A; Liovas A
    Can Respir J; 2007; 14(5):269-75. PubMed ID: 17703241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care.
    Price DB; Appleby JL
    Respir Med; 1998 Feb; 92(2):351-3. PubMed ID: 9616537
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative clinical effectiveness of long-term controller therapy for asthma.
    Kelly HW
    Ann Allergy Asthma Immunol; 1999 Oct; 83(4):269-70. PubMed ID: 10541418
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
    O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma.
    Booth PC; Wells NE; Morrison AK
    Pharmacoeconomics; 1996 Sep; 10(3):262-8. PubMed ID: 10163573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flixotide Nebules: new for chronic severe asthma.
    Mukherjee SK
    Hosp Med; 1999 Jun; 60(6):442-3. PubMed ID: 10492718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.